Buerger’s Disease (BD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Buerger’s Disease (BD) Market Outlook

Thelansis’s “Buerger’s Disease (BD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Buerger’s Disease (BD)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Buerger’s Disease (BD) Overview

Buerger’s Disease, or Thromboangiitis obliterans (TAO), is a distinctive nonatherosclerotic and segmental inflammatory condition primarily affecting the small and medium-sized arteries and veins in the extremities. This vascular disorder is characterized by acute-phase lesions, marked by occlusive cellular thrombosis and inflammation spanning all vessel wall layers, earning it the classification of vasculitis. Despite extensive research, there is no consistent pattern in HLA haplotypes among individuals with Buerger’s disease. However, in European nations, there appears to be a higher prevalence of HLA-A9 and HLA-B5 antigens, suggesting a possible genetic component in certain populations. The primary demographic at heightened risk for Buerger’s disease consists of heavy smokers. Particularly susceptible are men of Eastern European descent under the age range of 20 to 40. This specific demographic subgroup demonstrates an increased vulnerability to the disease. Additionally, the association between Buerger’s disease and tobacco use extends beyond traditional cigarette smokers, encompassing cigar smokers, marijuana users, and individuals who partake in smokeless tobacco, such as chewing tobacco and snuff. The identification of these risk factors underscores the crucial role of tobacco consumption in the development of Buerger’s disease. Public health initiatives and targeted interventions aimed at reducing tobacco use may contribute significantly to the prevention and management of this unique and challenging vascular disorder.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Buerger’s Disease (BD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment